Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

Recruiting

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Peking University Third Hospital, Beijing, Beijing Municipality